Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.

Dimopoulos MA, Laubach JP, Echeveste Gutierrez MA, Grzasko N, Hofmeister CC, San-Miguel JF, Kumar S, Labotka R, Lu V, Berg D, Byrne C, Teng Z, Liu G, van de Velde H, Richardson PG.

Eur J Haematol. 2019 Jun;102(6):494-503. doi: 10.1111/ejh.13231. Epub 2019 May 8.

PMID:
30943323
2.

Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

Hulin C, de la Rubia J, Dimopoulos MA, Terpos E, Katodritou E, Hungria V, De Samblanx H, Stoppa AM, Aagesen J, Sargin D, Sioni A, Belch A, Diels J, Olie RA, Robinson D Jr, Potamianou A, van de Velde H, Delforge M.

Health Sci Rep. 2018 Dec 7;2(1):e104. doi: 10.1002/hsr2.104. eCollection 2019 Jan.

3.

Influence of ultra-low oxygen (2%) tension on in-vitro human embryo development.

De Munck N, Janssens R, Segers I, Tournaye H, Van de Velde H, Verheyen G.

Hum Reprod. 2019 Feb 1;34(2):228-234. doi: 10.1093/humrep/dey370.

PMID:
30576441
4.

BMP4 plays a role in apoptosis during human preimplantation development.

De Paepe C, Aberkane A, Dewandre D, Essahib W, Sermon K, Geens M, Verheyen G, Tournaye H, Van de Velde H.

Mol Reprod Dev. 2019 Jan;86(1):53-62. doi: 10.1002/mrd.23081. Epub 2018 Nov 23.

PMID:
30372558
5.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Oct;101(4):556-565. doi: 10.1111/ejh.13147. Epub 2018 Sep 5.

PMID:
30027641
6.

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.

Jin J, Okamoto R, Yoon SS, Shih LY, Zhu J, Liu T, Hong X, Pei L, Rooney B, van de Velde H, Huang H.

Onco Targets Ther. 2018 Jul 6;11:3869-3882. doi: 10.2147/OTT.S150339. eCollection 2018.

7.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S.

Haematologica. 2018 Sep;103(9):1518-1526. doi: 10.3324/haematol.2017.185991. Epub 2018 Jun 28.

8.

Random Mutagenesis, Clonal Events, and Embryonic or Somatic Origin Determine the mtDNA Variant Type and Load in Human Pluripotent Stem Cells.

Zambelli F, Mertens J, Dziedzicka D, Sterckx J, Markouli C, Keller A, Tropel P, Jung L, Viville S, Van de Velde H, Geens M, Seneca S, Sermon K, Spits C.

Stem Cell Reports. 2018 Jul 10;11(1):102-114. doi: 10.1016/j.stemcr.2018.05.007. Epub 2018 Jun 14.

9.

Expression of adhesion and extracellular matrix genes in human blastocysts upon attachment in a 2D co-culture system.

Aberkane A, Essahib W, Spits C, De Paepe C, Sermon K, Adriaenssens T, Mackens S, Tournaye H, Brosens JJ, Van de Velde H.

Mol Hum Reprod. 2018 Jul 1;24(7):375-387. doi: 10.1093/molehr/gay024.

PMID:
29846687
10.

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1.

Garderet L, Laubach JP, Stoppa AM, Hari P, Cavo M, Ludwig H, Mateos MV, Luptakova K, Lin J, Yung G, van de Velde H, Berg D, Moreau P, Richardson PG.

Leukemia. 2018 Sep;32(9):2032-2036. doi: 10.1038/s41375-018-0091-3. Epub 2018 Mar 12. No abstract available.

11.

Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.

Gupta N, Hanley MJ, Diderichsen PM, Yang H, Ke A, Teng Z, Labotka R, Berg D, Patel C, Liu G, van de Velde H, Venkatakrishnan K.

Clin Pharmacol Ther. 2019 Feb;105(2):376-387. doi: 10.1002/cpt.1047. Epub 2018 Mar 23. Review.

12.

Obstetric and neonatal outcome following ICSI with assisted oocyte activation by calcium ionophore treatment.

Mateizel I, Verheyen G, Van de Velde H, Tournaye H, Belva F.

J Assist Reprod Genet. 2018 Jun;35(6):1005-1010. doi: 10.1007/s10815-018-1124-6. Epub 2018 Feb 1.

13.

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.

Drach J, Huang H, Samoilova O, Belch A, Farber C, Bosly A, Novak J, Zaucha J, Dascalescu A, Bunworasate U, Masliak Z, Vilchevskaya K, Robak T, Pei L, Rooney B, van de Velde H, Cavalli F.

Leuk Lymphoma. 2018 Apr;59(4):896-903. doi: 10.1080/10428194.2017.1365855. Epub 2018 Jan 17.

PMID:
29338540
14.

Birthweight of singletons born after cleavage-stage or blastocyst transfer in fresh and warming cycles.

De Vos A, Santos-Ribeiro S, Van Landuyt L, Van de Velde H, Tournaye H, Verheyen G.

Hum Reprod. 2018 Feb 1;33(2):196-201. doi: 10.1093/humrep/dex361.

PMID:
29206936
15.

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC.

Invest New Drugs. 2018 Aug;36(4):619-628. doi: 10.1007/s10637-017-0531-3. Epub 2017 Nov 2.

PMID:
29094232
16.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.

Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.

17.

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Richardson PG, Kumar S, Laubach JP, Paba-Prada C, Gupta N, Berg D, van de Velde H, Moreau P.

J Blood Med. 2017 Aug 22;8:107-121. doi: 10.2147/JBM.S102328. eCollection 2017. Review.

18.

Deregulation of the endometrial stromal cell secretome precedes embryo implantation failure.

Peter Durairaj RR, Aberkane A, Polanski L, Maruyama Y, Baumgarten M, Lucas ES, Quenby S, Chan JKY, Raine-Fenning N, Brosens JJ, Van de Velde H, Lee YH.

Mol Hum Reprod. 2017 Aug 1;23(8):582. doi: 10.1093/molehr/gax037. No abstract available.

PMID:
28810693
19.

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Hanley MJ, Gupta N, Venkatakrishnan K, Bessudo A, Sharma S, O'Neil BH, Wang B, van de Velde H, Nemunaitis J.

J Clin Pharmacol. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Epub 2017 Aug 7.

PMID:
28783865
20.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P.

Haematologica. 2017 Oct;102(10):1767-1775. doi: 10.3324/haematol.2017.170118. Epub 2017 Jul 27.

21.

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.

Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P.

J Hematol Oncol. 2017 Jul 6;10(1):137. doi: 10.1186/s13045-017-0501-4.

22.

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F.

Leuk Lymphoma. 2019 Jan;60(1):172-179. doi: 10.1080/10428194.2017.1321750. Epub 2017 Jun 5.

PMID:
28583031
23.

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG.

Br J Haematol. 2017 Aug;178(4):547-560. doi: 10.1111/bjh.14708. Epub 2017 May 3.

PMID:
28466536
24.

Deregulation of the endometrial stromal cell secretome precedes embryo implantation failure.

Peter Durairaj RR, Aberkane A, Polanski L, Maruyama Y, Baumgarten M, Lucas ES, Quenby S, Chan JKY, Raine-Fenning N, Brosens JJ, Van de Velde H, Lee YH.

Mol Hum Reprod. 2017 Jul 1;23(7):478-487. doi: 10.1093/molehr/gax023. Erratum in: Mol Hum Reprod. 2017 Aug 1;23(8):582.

PMID:
28402555
25.

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K.

Clin Pharmacokinet. 2017 Nov;56(11):1355-1368. doi: 10.1007/s40262-017-0526-4.

26.

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.

Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, van de Velde H, Cavalli F.

Haematologica. 2017 May;102(5):895-902. doi: 10.3324/haematol.2016.152496. Epub 2017 Feb 9.

27.

Mitotic spindle disruption in human preimplantation embryos activates the spindle assembly checkpoint but not apoptosis until Day 5 of development.

Jacobs K, Van de Velde H, De Paepe C, Sermon K, Spits C.

Mol Hum Reprod. 2017 May 1;23(5):321-329. doi: 10.1093/molehr/gax007.

PMID:
28159965
28.

The role of methylation, DNA polymorphisms and microRNAs on HLA-G expression in human embryonic stem cells.

Verloes A, Spits C, Vercammen M, Geens M, LeMaoult J, Sermon K, Coucke W, Van de Velde H.

Stem Cell Res. 2017 Mar;19:118-127. doi: 10.1016/j.scr.2017.01.005. Epub 2017 Jan 9.

29.

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.

Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A.

Leuk Lymphoma. 2017 Aug;58(8):1968-1972. doi: 10.1080/10428194.2016.1272688. Epub 2017 Jan 16. No abstract available.

PMID:
28092998
30.

Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.

van de Velde H, Londhe A, Ataman O, Johns HL, Hill S, Landers E, Berlin JA.

Eur J Haematol. 2017 Mar;98(3):269-279. doi: 10.1111/ejh.12829. Epub 2016 Dec 17.

PMID:
27859769
31.

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.

Mateos MV, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS.

Ann Hematol. 2016 Dec;95(12):2033-2041. Epub 2016 Oct 14.

PMID:
27738789
32.

Do ARTs affect the incidence of monozygotic twinning?

Mateizel I, Santos-Ribeiro S, Done E, Van Landuyt L, Van de Velde H, Tournaye H, Verheyen G.

Hum Reprod. 2016 Nov;31(11):2435-2441. Epub 2016 Sep 22.

PMID:
27664211
33.

Cumulative live birth rates after fresh and vitrified cleavage-stage versus blastocyst-stage embryo transfer in the first treatment cycle.

De Vos A, Van Landuyt L, Santos-Ribeiro S, Camus M, Van de Velde H, Tournaye H, Verheyen G.

Hum Reprod. 2016 Nov;31(11):2442-2449. Epub 2016 Sep 12.

PMID:
27619768
34.

The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.

Robinson D Jr, Esseltine DL, Regnault A, Meunier J, Liu K, van de Velde H.

Br J Haematol. 2016 Aug;174(3):368-81. doi: 10.1111/bjh.14058. Epub 2016 Jun 5.

35.

Similar kinetics for 5-methylcytosine and 5-hydroxymethylcytosine during human preimplantation development in vitro.

Petrussa L, Van de Velde H, De Rycke M.

Mol Reprod Dev. 2016 Jul;83(7):594-605. doi: 10.1002/mrd.22656. Epub 2016 Jun 24.

PMID:
27163211
36.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group.

N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

37.

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F.

Clin Cancer Res. 2016 Aug 15;22(16):4206-4214. doi: 10.1158/1078-0432.CCR-15-2793. Epub 2016 Mar 22.

38.

Closed oocyte vitrification and storage in an oocyte donation programme: obstetric and neonatal outcome.

De Munck N, Belva F, Van de Velde H, Verheyen G, Stoop D.

Hum Reprod. 2016 May;31(5):1024-33. doi: 10.1093/humrep/dew029. Epub 2016 Mar 2.

PMID:
26936884
39.

Open versus closed oocyte vitrification in an oocyte donation programme: a prospective randomized sibling oocyte study.

De Munck N, Santos-Ribeiro S, Stoop D, Van de Velde H, Verheyen G.

Hum Reprod. 2016 Feb;31(2):377-84. doi: 10.1093/humrep/dev321. Epub 2016 Jan 2.

PMID:
26724798
40.

Cyclin E1 plays a key role in balancing between totipotency and differentiation in human embryonic cells.

Krivega MV, Geens M, Heindryckx B, Santos-Ribeiro S, Tournaye H, Van de Velde H.

Mol Hum Reprod. 2015 Dec;21(12):942-56. doi: 10.1093/molehr/gav053. Epub 2015 Sep 27.

PMID:
26416983
41.

A prospective randomized controlled trial investigating the effect of artificial shrinkage (collapse) on the implantation potential of vitrified blastocysts.

Van Landuyt L, Polyzos NP, De Munck N, Blockeel C, Van de Velde H, Verheyen G.

Hum Reprod. 2015 Nov;30(11):2509-18. doi: 10.1093/humrep/dev218. Epub 2015 Sep 12.

PMID:
26364080
42.

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.

van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R.

Oncotarget. 2015 Oct 6;6(30):30408-19. doi: 10.18632/oncotarget.4655.

43.

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, Ferhanoglu B.

Blood. 2015 Oct 15;126(16):1893-901. doi: 10.1182/blood-2015-03-632430. Epub 2015 Jul 31.

44.

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L.

Br J Haematol. 2015 Nov;171(3):344-54. doi: 10.1111/bjh.13582. Epub 2015 Jul 7.

45.

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.

Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Hall B, van de Velde H, Vermeulen J, Reddy M, van Rhee F.

Clin Cancer Res. 2015 Oct 1;21(19):4294-304. doi: 10.1158/1078-0432.CCR-15-0134. Epub 2015 Jun 29.

46.

WNT3 and membrane-associated β-catenin regulate trophectoderm lineage differentiation in human blastocysts.

Krivega M, Essahib W, Van de Velde H.

Mol Hum Reprod. 2015 Sep;21(9):711-22. doi: 10.1093/molehr/gav036. Epub 2015 Jun 24.

PMID:
26108805
47.

DAZL regulates Tet1 translation in murine embryonic stem cells.

Welling M, Chen HH, Muñoz J, Musheev MU, Kester L, Junker JP, Mischerikow N, Arbab M, Kuijk E, Silberstein L, Kharchenko PV, Geens M, Niehrs C, van de Velde H, van Oudenaarden A, Heck AJ, Geijsen N.

EMBO Rep. 2015 Jul;16(7):791-802. doi: 10.15252/embr.201540538. Epub 2015 Jun 15.

48.

Deposition of the spermatozoon in the human oocyte at ICSI: impact on oocyte survival, fertilization and blastocyst formation.

De Vos A, Abraham M, Franceus N, Haentjens P, Tournaye H, Verheyen G, Van de Velde H.

J Assist Reprod Genet. 2015 Jun;32(6):865-71. doi: 10.1007/s10815-015-0482-6. Epub 2015 May 1.

49.

Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.

Chaturvedi S, Siegel D, Wagner CL, Park J, van de Velde H, Vermeulen J, Fung MC, Reddy M, Hall B, Sasser K.

Br J Clin Pharmacol. 2015 Oct;80(4):687-97. doi: 10.1111/bcp.12652. Epub 2015 Jun 4.

50.

Chromosomal meiotic segregation, embryonic developmental kinetics and DNA (hydroxy)methylation analysis consolidate the safety of human oocyte vitrification.

De Munck N, Petrussa L, Verheyen G, Staessen C, Vandeskelde Y, Sterckx J, Bocken G, Jacobs K, Stoop D, De Rycke M, Van de Velde H.

Mol Hum Reprod. 2015 Jun;21(6):535-44. doi: 10.1093/molehr/gav013. Epub 2015 Mar 31.

PMID:
25833840

Supplemental Content

Loading ...
Support Center